Invasive aspergillosis: New insights into disease, diagnostic and treatment

Current Pharmaceutical Design

Volumn 19, Issue 20, 2013, Pages 3569-3594

  Karthaus, Meinolf ^a   Buchheidt, Dieter ^b  

^a Klinikum Neuperlach   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Diagnostic treatment; Invasive aspergillosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; DIAZEPAM; ECHINOCANDIN; FELODIPINE; FLUCONAZOLE; HYDROXYITRACONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; LEVACETYLMETHADOL; METHADONE; MICAFUNGIN; NIFEDIPINE; NISOLDIPINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PLACEBO; POSACONAZOLE; QUINIDINE; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL; VORICONAZOLE;

ABNORMAL VISION; ACUTE KIDNEY FAILURE; ANOREXIA; AREA UNDER THE CURVE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; ASTHMA; BRONCHOSPASM; CANDIDA ALBICANS; CENTRAL NERVOUS SYSTEM ASPERGILLOSIS; CHILL; COMPARATIVE STUDY; CONTINUOUS INFUSION; COUGHING; CRYPTOCOCCUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FORMULATION; FEBRILE NEUTROPENIA; FEVER; FUNGAL STRAIN; FUSARIOSIS; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPOTENSION; IN VITRO STUDY; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MICROSCOPY; MOLECULAR DIAGNOSIS; MONOTHERAPY; MORTALITY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; OPEN STUDY; OVERALL SURVIVAL; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RIGOR; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHOCK; SYSTEMIC MYCOSIS; TACHYPNEA; TORSADE DES POINTES; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG DESIGN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCOMPROMISED HOST; RISK FACTORS;

EID: 84878623072     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990330     Document Type: Review

References (223)

1. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 2012; 73(4): 293-300.
2. Donhuijsen K, Petersen P, Schmid WK. Trend reversal in the frequency of mycosis in hematological neoplasias: autopsy results from 1976 to 2005. Dtsch Arztebl Int 2008; 105(28-29): 501-6
3. Lass-Flörl. The changing face of epidemiology in Europe. Mycoses 2009; 52(3): 197-205
4. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosisrelated hospitalizations in the United States. Clin Infect Dis 2000; 31(6): 1524-8. Erratum in: Clin Infect Dis 2001; 32(4): 673.
5. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
6. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95(4): 644-50.
7. Karthaus M, Doellmann, Klimasch T, et al. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled study in acute leukemia patients. Chemotherapy 2000; 46(4): 293-302.
8. Vehreschild JJ, Böhme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007; 55(5): 445-49.
9. Mikulska M, Raiola AM, Bruno B, Furfaro E, et al. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009; 44(6): 361-70.
10. Michallet M, Sobh M, Morisset S, et al. Risk factors for invasive aspergillosis in acute myeloid leukaemia patients treated prophylactically with posaconazole. Med Mycol 2011; 49(7): 681-7.
11. Michaellet M, Bénet T, Sobh M, et al. Invasive aspergillosis: an important risk factor on the short and long-term survival of acute myeloid leukaemia (AML) patients. Eur J Clin Microbiol Infect Dis 2012; 31(6): 991-7.
12. Cordonnier C, Ribaud P, Herbrecht R, et al. Societé Francaise de Greffe de Moelle et de Therapie Celluaire. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: A 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006; 42(7): 955-63.
13. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50(8): 1091-100.
14. Steinbach WJ, Marr KA, Anaissie EJ, et al. Clinical Epidemiologiy of 960 patients with invasive Aspergillosis from the PATH Alliance registry. J Infect 2012 Aug 13. [Epub ahead of print].
15. Lortholary O, Gangneux JP, Sitbon K, et al. French Mycosis Study Group. Epidemiological trends in invasive aspergillosis in France: the SAIF network (205-2007). Clin Microbiol Infect 2011; 17(12): 1882-9.
16. Auberger J, Lass-Flörl C, Ulmer H, et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2008; 88(5): 508-15.
17. Nicolle MC, Bénet T, Thiebaut A, et al. Invasive aspergillosis in patients with haematological malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica 2011; 96(11): 1685-91.
18. Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131(2): 201-7.
19. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44(4): 531-40.
20. Stevens DA, KanVL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
21. Rex JH, Walsh TJ, Anaissie EA. Fungal infections in iatrogenically compromised hosts. Adv Intern Med 1998; 43: 321-71
22. Leenders AC, van Belkum A, Behrendt M, Luijendijk A, Verbrugh HA. Density and molecular epidemiology of Aspergillus in air and relationship to outbreaks of Aspergillus infection. J Clin Microbiol 1999; 37(6): 1752-7.
23. Labori M, Garcia-Vidal C, Peghin M, et al. Environmental variables associated with an increased risk of invasive aspergillosis, Proceedings 52th ICAAC; 9.-12. Sep 2012; Abstract M-1228.
24. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
25. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46(12): 1813-21.
26. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66: 257-62.
27. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002; 34(6): 780-9.
28. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53(RR-3): 1-36.
29. Nihitinen A, Antilla VJ, Richardson M, Meri T, Volin L, Ruutu T. The utility of intensified environmental surveillance for pathologic mould in a stem cell transplantation ward during construction work to monitor the efficacy of HEPA filtration. Bone Marrow Transplant 2007; 40(5): 457-60.
30. Adul Salam ZH, Karlin RB, Ling ML, Yang KS. The impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a large acute tertiary-care hospital. Am J Infect Control 2010; 38(4): e1-7.
31. Loo VG, Bertrand C, Dixon C, et al. Control of constructionassociated nosocomial aspergillosis in an antiquated haematology unit. Infect Control Hosp Epidemiol 1996; 17(6): 360-4.
32. Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL jr. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immuncompromised patients with hematological malignancies. Infect Control Hosp Epidemiol 2002; 23(9): 525-31
33. Krüger WH, Zöllner B, Kauffers PM, Zander AR. Effective protection of allogeneic stem cell recipients against aspergillosis by HEPA air filtration during a construction period-a prospective survey. J Hematother Stem Cell Res 2003; 12(3): 301-7.
34. Cornet M, Levy V, Fleury L, et al. Efficacy of prevention by highefficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 1999; 20(7): 508-13.
35. Engelhart S, Hanfland J, Glasmacher A, Krizek L, Schmidt-Wolf IG, Exner M. Impact of portable air filtration units on exposure of haematology patients to airborne Aspergillus fumigatus spores under field conditions. J Hosp Infect 2003; 54(4): 300-4
36. Lee LD, Berkheiser Mjiang Y, Hackett B, Hachem RY, Chemaly RF, Raad II. Risk of bioaerosole contamination with Aspergillus species before and after cleaning in rooms filtered with highefficiency particulate air filters that house patients with haematological malignancies. Infect Control Hosp Epidemiol 2007; 28(9): 1066-70
37. Falvey DG, Streifel AJ. Ten-year air sample analysis of Aspergillus prevalence in a university hospital. J Hosp Infect 2007; 67(1): 35-41.
38. Vonberg RP, Gastmeier P. Nosocomial aspergillosis in the outbreak setting. J Hosp Infect 2006; 63(3): 246-54.
39. Maschmeyer G, Neuburger S, Fritz L, et al. Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. A prospective, randomised study of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol 2009; 20(9): 1560-4.
40. Lehrnbecher T, Frank C, Engels K, Kriener S, Groll AH, Schwabe D. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 2010; 61 (3): 259-65
41. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33(1): 23-32
42. Ascioglu S, Rex JH, de Pauw B, et al. Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002; 34(1): 7-14.
43. Herbrecht R, Caillot D, Cordonnier C, et al. Indications and outcome of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation. J Antimicrob Chemother 2012.
44. Cornely OA, Maertens J, Bresnik M, et al. AmBiLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44(10): 1289-97.
45. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33(1): 23-32
46. Wingard JR, Ribaud P, Schlamm HT, Herbrecht R. Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 2008; 112(10): 2309-12.
47. Maertens JJ. Van Eldere J. Verhaegen E, Verbeken J, Verschakelen M. Boogaerts Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infec Dis 2002; 186: 1297-306
48. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003; 101(9): 3365-72.
49. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000; 31(1): 188-9.
50. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 2001; 33(11): 1824-33
51. Andreas S, Heindl S, Wattky C, et al. Diagnosis of pulmonary aspergillosis using optical brighteners. Eur Respir J 2000; 15(2): 407-11
52. Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009; 45(14): 2462-72.
53. Kyo K, Ochi T, Oktani T, et al. Is halo sign the earliest sign of invasive aspergillosis? 52th Proceedings ICAAC, 9.-12. Sep 2012; abstract M-1226
54. Heussel CP, Kauczor HU, Heussel G, et al. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. AJR Am J Roentgenol 1997; 169(5): 1347-53.
55. Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999; 17(3): 796-805.
56. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15(1): 139-47.
57. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19(1): 253-9.
58. Horger M, Hebart H, Einsele H, et al. Initial CT manifestations of invasive pulmonary aspergillosis in 45 non-HIV immunocompromised patients: association with patient outcome? Eur J Radiol 2005; 55(3): 437-44.
59. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44(3): 373-9.
60. Bergeron A, Porcher R, Sulahian A, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 2012; 119(8): 1831-7.
61. Ruhnke M, Böhme A, Buchheidt D, et al. Infectious Diseases Working Party in Haematology and Oncology (AGIHO) of the German Society for Haematology and Oncology (DGHO). Diagnosis of invasive fungal infections in hematology and oncology-guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO). Ann Oncol 2012; 23(4): 823-33.
62. Andrews CP, Weiner MH. Aspergillus antigen detection in bronchoalveolar lavage fluid from patients with invasive aspergillosis and aspergillomas. Am J Med 1982; 73: 372-80.
63. Stynen D, Goris A, Sarfati J, Latge JP. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497-500.
64. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223-8.
65. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-10.
66. Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126: 852-60.
67. Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3)-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 2010; 54(11): 4879-86.
68. Petraitiene R, Petraitis V, Witt JR 3rd, et al. Galactomannan antigenemia after infusion of gluconate-containing Plasma-Lyte. J Clin Microbiol 2011; 49(12): 4330-2.
69. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40(12): 1762-9.
70. Maertens J, Theunissen K, Verhoef G, Van Eldere J. False positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004; 39: 289-90.
71. Wheat LJ, Walsh TJ. Diagnosis of invasive aspergillosis by galactomannan antigenemia detection using an enzyme immunoassay. Eur J Clin Microbiol Infect Dis 2008; 27(4): 245-51.
72. Reichenberger F, Habicht J, Matt P, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. BMT 1999; 24(11): 1195-9.
73. Hummel M, Rudert S, Hof H, Hehlmann R, Buchheidt D. Diagnostic yield of bronchoscopy with bronchoalveolar lavage in febrile patients with hematologic malignancies and pulmonary infiltrates. Ann Hematol 2008 87(4): 291-7.
74. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der SC, Hoogsteden HC, De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121(3): 448-57.
75. Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review. Chest 2010; 138(4): 817-24.
76. Sampsonas F, Kontoyiannis DP, Dickey BF, Evans SE. Performance of a standardized bronchoalveolar lavage protocol in a comprehensive cancer center: a prospective 2-year study. Cancer 2011; 117(15): 3424-33.
77. Bergeron A, Belle A, Sulahian A, et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 2010; 137(2): 410-5.
78. Nguyen MH, Leather H, Clancy CJ, et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary Aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 2011; 17: 1043-50.
79. Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar Lavage Fluid Galactomannan for the Diagnosis of Invasive Pulmonary Aspergillosis in Patients with Hematologic Diseases. Clin Infect Dis 2009; 49: 1688-93.
80. D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50(4): 1258-63.
81. Racil Z, Kocmanova I, Toskova M, et al. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infectious Diseases 2011; 15: e874-e81
82. Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45(4): 647-55.
83. Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42(12): 5517-22.
84. Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol 2012; 89(2): 120-7.
85. Obayashi T, Yoshida M, Mori T, et al. Plasma (1->3)-beta-Dglucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 17-20.
86. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
87. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
88. Lu Y, Chen YQ, Guo YL, Qin SM, Wu C, Wang K. Diagnosis of invasive fungal disease using serum (1→3)-β-D-glucan: a bivariate meta-analysis. Intern Med 2011; 50(22): 2783-91.
89. Sarfati J, Monod M, Recco P, et al. Recombinant antigens as diagnostic markers for aspergillosis. Diagn Microbiol Infect Dis 2006; 55: 279-91.
90. Buchheidt D, Hummel M. Aspergillus polymerase chain reaction (PCR) diagnosis. Med Mycol 2005; 43 (Suppl 1): S139-S45.
91. Reichard U, Buchheidt D, Las-Flörl C, et al. Interlaboratory comparison of PCR-based identification of Candida and Aspergillus DNA in spiked blood samples. Mycoses 2012; 55(5): 426-34.
92. White PL, Bretagne S, Klingspor L, et al. European Aspergillus PCR Initiative. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48(4): 1231-40.
93. Buchheidt D, Hummel M, Schleiermacher D, Spiess B, Hehlmann R. Current molecular diagnostic approaches to systemic infections with Aspergillus species in patients with hematological malignancies. Leuk Lymphoma 2004; 45(3): 463-48.
94. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a way to go. Clin Infect Dis 2006; 42(4): 487-9.
95. Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997; 35(6): 1353-60.
96. Einsele H, Quabeck K, Muller KD, et al. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation. Lancet 1998; 352(9138): 1443.
97. Skladny H, Buchheidt D, Baust C, et al. Specific detection of Aspergillus species in blood and bronchoalveolar lavage samples of immunocompromised patients by two-step PCR. J Clin Microbiol 1999; 37(12): 3865-71.
98. Buchheidt D. Molecular diagnosis of invasive aspergillosis in patients with hematologic malignancies-new answers to a diagnostic challenge? Expert Opin Med Diagn 2008; 2(7): 753-61.
99. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9(2): 89-96.
100. Lass-Flörl C, Gunsilius E, Gastl G, et al. Diagnosing invasive aspergillosis during antifungal therapy by PCR analysis of blood samples. J Clin Microbiol 2004; 42(9): 4154-7.
101. Hummel M, Spiess B, Cornely OA, Dittmer M, Mörz H, Buchheidt D. Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial. Eur J Haematol 2010; 85(2): 164-9.
102. Tuon FF. A systematic literature review on the diagnosis of invasive aspergillosis using polymerase chain reaction (PCR) from bronchoalveolar lavage clinical samples. Rev Iberoam Micol 2007; 24(2): 89-94.
103. Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42(12): 5517-22.
104. Karthaus M, Hentrich M. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis. Mycoses 2011; 54 (Suppl 1): 1-6.
105. Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 2012; 67(9): 2260-7.
106. Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007; 44(8): 1078-83.
107. Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 2007; 45(7): e101-4.
108. Sun W, Wang K, Gao W, et al. Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate meta-analysis and systematic review. PLoS One 2011; 6(12): e28467.
109. Reichard U, Buchheidt D, Lass-Flörl C, et al. Interlaboratory comparison of PCR-based identification of Candida and Aspergillus DNA in spiked blood samples. Mycoses 2012; 55(5): 426-34.
110. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S. European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47(6): 846-54.
111. Miller CB, Waller EK, Klingemann HG, et al. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant 2004; 33: 543-8.
112. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36(8): 943-51.
113. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45(12): 3487-96.
114. Ito JI, Chandrasekar PH, Hooshmand-Rad R. Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis. Bone Marrow Transplant 2005; 36(10): 873-7.
115. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205-12.
116. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new "gold standard". Clin Infect Dis 2003; 37: 415-25
117. Wingard JR, White MH, Anaissie E, RAffalli J, Goodman J, Arrieta A, LAmph/ABLC Collaborative Study Group. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31(5): 1155-63.
118. Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001; 33(8): e83-90.
119. Soler-Palacín P, Frick MA, Martín-Nalda A, et al. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study. J Antimicrob Chemother 2012; 67(3): 700-6.
120. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46(2): 201-11.
121. Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. Clin Infect Dis 2012 Jul 30, epub ahaed of print
122. Heinz W, Höhl R, Karthaus M, Lipp HP, Scherer M. Optimierte Therapie invasiver Aspergillosen mit Voriconazol. Thieme Praxis Report 2012; 4(5): 1-16
123. Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50(1): 286-93.
124. Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascendingdose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006; 50(1): 279-85.
125. Perkhofer S, Lechner V, Lass-Flörl C. European Committee on Antimicrobial Susceptibility Testing. In vitro activity of Isavuconazole against Aspergillus species and Zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2009; 53(4): 1645-7.
126. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn Microbiol Infect Dis 2011; 71(4): 370-7.
127. Mora-Duarte J, Betts R, Rotstein C, et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347(25): 2020-9.
128. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356(24): 2472-82.
129. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45(7): 883-93.
130. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369(9572): 1519-27.
131. Ngai AL, Bourque MR, Lupinacci RJ, Strohmaier KM, Kartsonis NA. Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report. Int J Antimicrob Agents 2011; 38(6): 540-4.
132. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38(1): 47-51.
133. Nakagawa Y, Ichii Y, Saeki Y, Kodama M, Kishino S, Suzuki K. Effect of liver and kidney function on micafungin disposition in patients with hematologic malignancies. Eur J Drug Metab Pharmacokinet 2008; 33(3): 191-8.
134. Hirata K, Aoyama T, Matsumoto Y, et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 2007; 127(5): 897-901.
135. Kishino S, Ohno K, Shimamura T, Furukawatodo H. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 2004; 18(6): 676-80.
136. Hirata K, Aoyama T, Matsumoto Y, Ogawa F, Yamazaki H, Kikuti A, Yamamoto Y. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 2007; 127(5): 897-901.
137. Doria C, Bodzin AS, Vaccino S, Daskalakis C, Krawitz S, Ramirez CB. A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver function tests while on caspofungin. Clin Transplant 2011; 25(4): 569-75.
138. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28: 250-5.
139. Boogaerts M, Maertens J, van Hoof A, et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001; 48: 97-103.
140. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for longterm antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138(9): 705-13.
141. Glasmacher A, Prentice A, Gorschlüter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21(24): 4615-26.
142. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 Suppl 1: i17-i22.
143. Law D, Moore CB, Denning DW. Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother 1994; 38(7): 1561-6.
144. Marks DI, Paliuca A, Kibbler CC, et al. IMPROVIT Study Group. Voriconazole versus itraconazole for antifungal prophylaxis following allogneic hematopoietic stem cell transplantation. Br J Haematol 2011; 155(3): 318-27.
145. Wingard JR, Carter SL, Walsh TJ, et al. Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116(24): 5111-8.
146. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356(4): 335-47.
147. Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17(4): 507-15.
148. Hoenigl M, Raggam RB, Salzer HJ, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012; 39(6): 510-3.
149. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165(5): 891-7.
150. Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002; 71(4): 260-7.
151. Penack O, Schwartz S, Martus P, et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17(8): 1306-12.
152. Roth C, Gebhart J, Just-Neubling G, von Eisenhart-Rothe B, Beinhauer-Reeb I. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis. Infection 1996; 24: 354-60.
153. Niki Y, Bernard EM, Schmitt HJ, Tong WP, Edwards FF, Armstrong D. Pharmacokinetics of aerosol amphotericin B in rats. Antimicrob Agents Chemother 1990; 34: 29-32.
154. Ruijgrok EJ, Vulto AG, van Etten EWM. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol 2000; 52: 619-27.
155. Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93(11): 3654-61.
156. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aersosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebocontrolled trial. Clin Infect Dis 2008; 46(9): 1401-8.
157. Monforte V, Ussetti P, López R, et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009; 28(2): 170-5.
158. Borro JM, Solé A, de la Torre M, et al. Efficacy and safety of amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc 2008; 40(9): 3090-3.
159. Husain S, Capitano B, Corcoran T, et al. Intrapulmonary disposition of amphotericin B after aerosolized delivery of amphotericin B lipid complex (Abelcet; ABLC) in lung transplant recipients. Transplantation 2010; 90(11): 1215-9.
160. Bennett JE, Powers J, Walsh T, et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2003; 36(Suppl 3): S117-22.
161. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med 2000; 108(4): 282-9.
162. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer 1996; 32A(5): 814-20.
163. Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48(8): 1042-51.
164. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32(3): 358-66.
165. Herbrecht R, Denning DW, Patterson TF, et al. Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-15.
166. Herbrecht RT, Patterson TF, Slavin MA, et al. Application Of The 2008 Definitions For Invasive Fungal Diseases To The "Voriconazole vs Amphotericin B For Therapy Of Invasive Aspergillosis" Trial. A Collaborative EORTC / MSG Study (MSG 05). Proceedings 52th ICAAC; 9.-12. Sep 2012: M-1225
167. Jansen JP, Kern WV, Cornely OA, et al. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006; 9(1): 12-23. Erratum in: Value Health 2006; 9(5): 359.
168. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46(9): 1412-22.
169. Walsh TJ, Anaissie EJ, Denning DW, et al. Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46(3): 327-60.
170. Böhme A, Ruhnke M, Buchheidt D, et al. Maschmeyer G-Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Treatment of invasive fungal infections in cancer patients. Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88(2): 97-110.
171. Maertens J, Marchetti O, Herbrecht R, et al. Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem-cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant 2011; 46(5): 709-18.
172. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39(11): 1563-71.
173. Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer. Bone Marrow Transplant 2010; 45(7): 1227-33.
174. Viscoli C, Herbrecht R, Akan H, et al. Infectious Disease Group of the EORTC. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009; 64(6): 1274-81.
175. Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother 2011; 55(12): 5798-803.
176. Jeans AR, Howard SJ, Al-Nakeeb Z, et al. Combination of of voriconazole and anidulafungin for the treatment of triazole resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2012; jul 2012 Epub ahead of print.
177. van de Sande WW, Mathot RA, ten Kate MT, et al. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob Agents Chemother 2009; 53(5): 2005-13
178. Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect 2004; 10(10): 925-8.
179. Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination antifungal therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187(12): 1834-43.
180. Marr KA (Marr KA, Boeckh M, Carter RA, Kim HW, Corey. Combination of antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39 (6): 797-802.
181. Lellek H, Waldenmaer D, Dahlke J, et al. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Mycoses 2011; 54 (Suppl 1): 39-44.
182. Caesaro S, Toffolutti T, Messina C, et al. Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. Eur J Haematol 2004; 73(1): 50-5.
183. Yilmaz D, Balkan C, Ay Y, Akin M, Karapinar B, Kavakli K. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections. Mycoses 201; 54(3): 234-42.
184. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53(5): 337-49
185. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81(3): 320-6.
186. Marr KA, Schlamm H, Rottinghaus ST, et al. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. Proceedings 22nd ECCMID 2012 LB # 2812, London 21.03-3.4.2012
187. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47 (9); 2788-95.
188. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005; 56(Suppl 1): i33-36.
189. Caillot D. Intravenous itraconazole followed by oral itraconazole for the treatment of amphotericin-B-refractory invasive pulmonary aspergillosis. Acta Haematol 2003; 109(3): 111-1.
190. Cornely OA, Maertens J, Bresnik M, et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses 2011; 54(5): e449-55
191. Ruhnke, M, Kofla G, Otto K, Schwartz S. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007; 21(8): 659-76.
192. Reinwald M, Hummel M, Spiess B, et al. Evaluation of an Aspergillus PCR assay in cerebrospinal fluid samples of immunocompromised patients to detect cerebral aspergillosis. Proceedings 52nd ICAAC, 9.-12. Sep 2012; Abstract M-1704.
193. Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E. Poor efficacy of amphotericin-B-based therapy in CNS aspergillosis. Mycoses 2007; 50(3): 196-200.
194. Schwartz S, Reismann A, Troke PF. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection 2011; 39(3): 201-10.
195. Imai JK, Singh G, Fernandez B, Clemons KV, Stevens DA. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. Antimicrob Agents Chemother 2005; 56(1): 166-71.
196. Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004; 48(10): 4063-6.
197. Elter T, Sieniawski M, Gossmann A, et al. Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents 2006; 28(3): 262-5.
198. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis using voriconazole treatment. Blood 2005; 1006(8): 2641-5.
199. Fallon RM, Girotto JE. A review of clinical experience with newer antifungals in children. J Pediatr Pharmacol Ther 2008; 13(3): 124-40.
200. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44(1): 2-12.
201. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003; 98(2): 292-9.
202. Walsh TJ, Karlsson MD, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single or multiple-dose administration. Antimicrob Agent Chemother 2004; 48: 2166-72.
203. Schelenz S, Smith DA, Bancroft GJ. Cytokine and chemokine responses following pulmonary challenge with Aspergillus fumigatus: obligatory role of TNF-alpha and GM-CSF in neutrophil recruitment. Med Mycol 1999; 37(3): 183-94.
204. Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulocytemacrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996; 34(1): 63-9.
205. Roilides E, Lamaignere CG, Farmaki E. Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy. Int J Infect Dis 2002; 6(3): 154-63.
206. Bhatia S, McCullough J, Perry EH, Clay M, Ramsay NK, Neglia JP. Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation. Transfusion 1994; 34: 226-32.
207. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997; 11: 1621-30.
208. Stanworth SJ, Massey E, Hyde C, et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev 2005; (3): CD005339.
209. Steinbach WJ, Stevens DA. Review of newer antifungal and immunolatory strategies for invasive aspergillosis. Clin Infect Dis 2003; Suppl 3: S157-87.
210. Reichenberger F, Habicht JM, Gratwohl A, Tam M. Diagnosis and treatment of invasive pulmonary aspergillosis in neutropenic patients. Eur Respir J 2002; 19(4): 743-55.
211. Pagès PB, Abou Hanna H, Caillot D, Bernard A. Place of surgery in pulmonary aspergillosis and other pulmonary mycotic infections. Rev Pneumol Clin 2012; 68(2): 67-76.
212. Reichenberger F, Habicht J, Kaim A, et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am J Respir Crit Care Med 1998; 158: 885-90.
213. Danner BC, Didlis V, Dörge H, Mikroulis D, Bougioukas G, Schöndube FA. Surgical treatment of pulmonary aspergillosis/ mycosis in immunocompromised patients. Interact Cardiovasc Thorac Surg 2008; 7(5): 771-6.
214. Habicht JM, Matt P, Passweg JR, et al. Invasive pulmonary fungal infection in hematological patients: is resection effective? The Hematology J 2001; 2: 250-6.
215. Egli A, Fuller J, Humar A, et al. Emergence of Aspergillus calidoustus Infection in the Era of Posttransplantation Azole Prophylaxis. Transplantation 2012; 94(4): 403-10.
216. Aguillar-Guisado M, Martin-Pena A, Espigado I, et al. Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach. Haematologica 2012; 97(3): 464-71
217. Lafaurie M, Lapalu J, Raffoux E, et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect 201o; 16(8): 1191-6.
218. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125(1 Suppl): S3-13.
219. Snelders E, Camps SM, Karawajczyk A, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 2012; 7(3): e31801. Epub 2012 Mar 1.
220. Versteeg D, Snelders E, Rijs T, BSc-research. Continued azole resistance in Aspergillus fumigatus in Dutch hospitals. Proceedings 52nd ICAAC, 9.-12. Sep 2012; Abstract M-319.
221. Faria-Ramos I, Farinha S, Tavares P, Maia J, Ricardo E, Miranda IM, Pina-Vaz C, Rodrigues AG. Development of resistance to agriculture azole antifungal compounds: emergence of multidrug crossresistance among human fungal pathogens Candida, Cryptococcus, and Aspergillus. Proceedings 52nd ICAAC, 9.-12. Sep 2012; Abstract M-320.
222. Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/ myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012; 97(3): 459-63.
223. Ananda-Rajah MR, Slavin M, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis 2012; 25(1): 107-15.